High fat diet and GLP-1 drugs induce pancreatic injury in mice
详细信息 查看全文
- 作者：Rodney Rouse ; rodney.rouse@fda.hhs.gov" class="auth_mail ; Lin Xu ; Sharron Stewart ; Jun Zhang
- 关键词：GLP-1 ; glucagon-like-peptide-1 ; KC ; keratinocyte chemo-attractant ; DIP ; drug-induced pancreatitis ; EXE ; exenatide ; HFD ; high fat diet ; IL-1尾 ; interleukin-1尾 ; SIT ; sitigliptin ; STD ; standard diet ; TNF伪 ; tumor necrosis factor伪
- 刊名：Toxicology and Applied Pharmacology
- 出版年：15 April, 2014
- 年：2014
- 卷：276
- 期：2
- 页码：104-114
- 全文大小：3599 K
文摘
Glucagon Like Peptide-1 (GLP-1) drugs are currently used to treat type-2 diabetes. Safety concerns for increased risk of pancreatitis and pancreatic ductal metaplasia have accompanied these drugs. High fat diet (HFD) is a type-2 diabetes risk factor that may affect the response to GLP-1 drug treatment. The objective of the present study was to investigate the effects of diet and GLP-1 based drugs on the exocrine pancreas in mice. Experiments were designed in a mouse model of insulin resistance created by feeding a HFD or standard diet (STD) for 6 weeks. The GLP-1 drugs, sitagliptin (SIT) and exenatide (EXE) were administered once daily for additional 6 weeks in both mice fed HFD or STD. The results showed that body weight, blood glucose levels, and serum levels of pro-inflammatory cytokines (TNF伪, IL-1尾, and KC) were significantly greater in HFD mice than in STD mice regardless of GLP-1 drug treatment. The semi-quantitative grading showed that pancreatic changes were significantly greater in EXE and SIT-treated mice compared to control and that HFD exacerbated spontaneous exocrine pancreatic changes seen in saline-treated mice on a standard diet. Exocrine pancreatic changes identified in this study included acinar cell injury (hypertrophy, autophagy, apoptosis, necrosis, and atrophy), vascular injury, interstitial edema and inflammation, fat necrosis, and duct changes. These findings support HFD as a risk factor to increased susceptibility/severity for acute pancreatitis and indicate that GLP-1 drugs cause pancreatic injury that can be exacerbated in a HFD environment.